Cardiovascular disease in COPD: Mechanisms

Chest

Volumn 143, Issue 3, 2013, Pages 798-807

  MacLay, John D ^a   MacNee, William ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

AGING; ARTICLE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LOWEST INCOME GROUP; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; RISK FACTOR; SEDENTARY LIFESTYLE; SMOKING;

EID: 84874986674     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0938     Document Type: Article

References (119)

1. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2005; 2 (1): 35-41.
2. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2 (1): 8-11.
3. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002; 166 (3): 333-339.
4. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009; 179 (1): 35-40.
5. Mannino DM, Thorn D, Swensen A, Holguin F. Pre valence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32 (4): 962-969.
6. Basili S, Ferroni P, Vieri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999; 147 (2): 249-252.
7. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574-580.
8. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27 (5): 902-907.
9. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175 (3): 250-255.
10. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007; 4 (7): 522-525.
11. Agustí A, Edwards LD, Rennard SI, et al Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012; 7 (5): e37483.
12. Celli BR, Locantore N, Yates J, et al ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185 (10): 1065-1072.
13. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174 (8): 867-874.
14. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347 (20): 1557-1565.
15. Sin DD, Miller BE, Duvoix A, et al ECLIPSE Investigators. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 183 (9): 1187-1192.
16. Kraaijeveld AO, de Jager SC, de Jager WJ, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation. 2007; 116 (17): 1931-1941.
17. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 (21): 2195-2207.
18. Ridker PM, Cannon CP, Morrow D, et al Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352 (1): 20-28.
19. Sever PS, Poulter NR, Chang CL, et al ASCOT Investigators. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012; 33 (4): 486-494.
20. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007; 131 (4): 1006-1012.
21. Hurst JR, Hagan G, Wedzicha JA. Mechanism of statinassociated mortality reduction in COPD. Chest. 2007; 132 (4): 1409-1410.
22. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59 (12): 1690-1697.
23. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69 (2): 325-331.
24. Brekke PH, Omland T, Holmedal SH, Smith P, Søyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008; 31 (3): 563-570.
25. Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011; 66 (9): 775-781.
26. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005; 111 (25): 3481-3488.
27. Verma S, Li S-H, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105 (16): 1890-1896.
28. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001; 104 (9): 974-975.
29. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptordependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20 (9): 2094-2099.
30. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106 (12): 1439-1441.
31. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003; 107 (3): 398-404.
32. Luc G, Bard J-M, Juhan-Vague I, et al PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol. 2003; 23 (7): 1255-1261.
33. Boekholdt SM, Peters RJG, Hack CE, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2004; 24 (8): 1503-1508.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101 (15): 1767-1772.
35. Coulson JM, Rudd JH, Duckers JM, et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18 F-FDG PET pilot study. J Nucl Med. 2010; 51 (9): 1357-1360.
36. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C; Chronic Obstructive Bronchitis and Haemostasis Group. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost. 1994; 72 (3): 343-346.
37. Ashitani J-I, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002; 41 (3): 181-185.
38. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-874.
39. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax. 1991; 46 (7): 504-507.
40. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66 (9): 764-768.
41. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J. 2012; 39 (5): 1097-1103.
42. Schumacher A, Liebers U, John M, et al. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol. 2005; 142 (2): 370-376.
43. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001; 103 (4): 491-495.
44. Ferroni P, Basili S, Martini F, et al. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease [published correction appears in J Investig Med. 2000;48(3):217]. J Investig Med. 2000; 48 (1): 21-27.
45. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997; 77 (6): 1081-1085.
46. Harding SA, Sarma J, Josephs DH, et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004; 109 (16): 1926-1929.
47. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011; 66 (9): 769-774.
48. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003; 73 (3): 232-241.
49. van Gestel YRBM, Flu W-J, van Kuijk J-P, et al. Association of COPD with carotid wall intima-media thickness in vascular surgery patients. Respir Med. 2010; 104 (5): 712-716.
50. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2 (1): 50-60.
51. Lee YW, Kühn H, Hennig B, Neish AS, Toborek M. IL-4- induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol. 2001; 33 (1): 83-94.
52. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med. 1998; 132 (1): 9-15.
53. Aoki M, Nata T, Morishita R, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 2001; 38 (1): 48-55.
54. Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J. 2003; 24 (24): 2180-2185.
55. Mills NL, Törnqvist H, Robinson SD, et al. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation. 2005; 112 (25): 3930-3936.
56. Lattimore J-DL, Wilcox I, Nakhla S, Langenfeld M, Jessup W, Celermajer DS. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis. 2005; 179 (2): 255-259.
57. Ichikawa H, Flores S, Kvietys PR, et al. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ Res. 1997; 81 (6): 922-931.
58. Hartmann G, Tschöp M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine. 2000; 12 (3): 246-252.
59. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med. 2007; 175 (12): 1290-1297.
60. Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med. 2005; 172 (7): 915-920.
61. Thomson AJ, Drummond GB, Waring WS, Webb DJ, Maxwell SR. Effects of short-term isocapnic hyperoxia and hypoxia on cardiovascular function. J Appl Physiol. 2006; 101 (3): 809-816.
62. Skwarski KM, Morrison D, Barratt A, Lee M, MacNee W. Effects of hypoxia on renal hormonal balance in normal subjects and in patients with COPD. Respir Med. 1998; 92 (12): 1331-1336.
63. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002; 77 (1): 45-54.
64. Heindl S, Lehnert M, Criée CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001; 164 (4): 597-601.
65. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006; 27 (20): 2387-2393.
66. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994; 90 (2): 878-883.
67. Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994; 106 (5): 1432-1437.
68. Corretti MC, Anderson TJ, Benjamin EJ, et al International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39 (2): 257-265.
69. Barr RG, Mesia-Vela S, Austin JH, et al. Impaired flowmediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007; 176 (12): 1200-1207.
70. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178 (12): 1211-1218.
71. Laurent S, Cockcroft J, Van Bortel L, et al European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27 (21): 2588-2605.
72. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55 (13): 1318-1327.
73. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113 (5): 664-670.
74. Zureik M, Benetos A, Neukirch C, et al. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med. 2001; 164 (12): 2181-2185.
75. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175 (12): 1259-1265.
76. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008; 63 (4): 306-311.
77. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176 (12): 1208-1214.
78. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180 (6): 513-520.
79. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax. 2006; 61 (7): 568-571.
80. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012; 67 (7): 606-612.
81. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol. 2008; 105 (5): 1643-1651.
82. Dransfield MT, Huang F, Nath H, Singh SP, Bailey WC, Washko GR. CT emphysema predicts thoracic aortic calcification in smokers with and without COPD. COPD. 2010; 7 (6): 404-410.
83. McAllister DA, MacNee W, Duprez D, et al. Pulmonary function is associated with distal aortic calcium, not proximal aortic distensibility. MESA lung study. COPD. 2011; 8 (2): 71-78.
84. Bolton CE, Mceniery CM, Raj V, et al. Aortic calcification, arterial stiffness and bone mineral density in patients with COPD. Artery Res. 2011; 5 (1): 30-36.
85. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999; 13 (1): 197-205.
86. Uitto J. The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J Drugs Dermatol. 2008; 7 (suppl 2): s12 - s16.
87. Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010; 74 (11): 2257-2262.
88. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans. 2009; 37 (pt 4): 819-823.
89. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179 (7): 566-571.
90. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006; 174 (8): 886-893.
91. Yokohori N, Aoshiba K, Nagai A; Respiratory Failure Research Group in Japan. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest. 2004; 125 (2): 626-632.
92. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001; 163 (3 pt 1): 737-744.
93. Tuder RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc. 2006; 3 (8): 673-679.
94. Amsellem V, Gary-Bobo G, Marcos E, et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 184 (12): 1358-1366.
95. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem. 2006; 75 : 435-465.
96. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 177 (8): 861-870.
97. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002; 105 (13): 1541-1544.
98. Bürrig KF. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler Thromb. 1991; 11 (6): 1678-1689.
99. Benetos A, Okuda K, Lajemi M, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001; 37 (2 pt 2): 381-385.
100. B rouilette SW, Moore JS, McMahon AD, et al; West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested casecontrol study. Lancet. 2007; 369 (9556): 107-114.
101. Ota H, Eto M, Ogawa S, Iijima K, Akishita M, Ouchi Y. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. J Atheroscler Thromb. 2010; 17 (5): 431-435.
102. B araldo S, Bazzan E, Zanin ME, et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest. 2007; 132 (6): 1733-1740.
103. Cataldo D, Munaut C, Noël A, et al. MMP-2- and MMP-9- linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2000; 123 (3): 259-267.
104. Li Z, Li L, Zielke HR, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol. 1996; 148 (1): 121-128.
105. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995; 91 (8): 2125-2131.
106. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372.
107. Ito I, Nagai S, Handa T, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med. 2005; 172 (11): 1378-1382.
108. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003; 4 : 11.
109. B olton C E, S tone M D, E dwards P H, D uckers J M, E vans W D, Shale DJ. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2009; 6 (2): 81-87.
110. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A. 1995; 92 (2): 402-406.
111. G alis Z S, S ukhova G K, L ark M W, L ibby P. I ncreased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94 (6): 2493-2503.
112. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004; 24 (8): 1479-1484.
113. Janoff A, Sloan B, Weinbaum G, et al. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis. 1977; 115 (3): 461-478.
114. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol. 2003; 163 (6): 2329-2335.
115. D ollery C M, O wen C A, S ukhova G K, K rettek A, S hapiro S D, Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation. 2003; 107 (22): 2829-2836.
116. S mith FB, Fowkes FG, Rumley A, Lee AJ, Lowe GD, Hau CM. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J. 2000; 21 (19): 1607-1613.
117. G olovatch P, M ercer B A, L emaître V, W allace A, F oronjy R F, D'Armiento J. Role for cathepsin K in emphysema in smokeexposed guinea pigs. Exp Lung Res. 2009; 35 (8): 631-645.
118. Lutgens E, Lutgens SPM, Faber BCG, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation. 2006; 113 (1): 98-107.
119. Z ucker S, Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther. 2009; 8 (24): 2371-2373.